A mechanism-based pharmacokinetic/pharmacodynamic (PK/PD) model for omalizumab (rhuMAb-E25).

被引：0
|
作者：
Sun, YN [1 ]
Marian, M [1 ]
Schoenhoff, M [1 ]
Sinclair, D [1 ]
Fick, R [1 ]
机构：
[1] Genentech Inc, S San Francisco, CA 94080 USA
来源：
CLINICAL PHARMACOLOGY & THERAPEUTICS | 2001年 / 69卷 / 02期
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
引用
收藏
页码：P87 / P87
页数：1
相关论文
共 50 条
  • [41] A UNIFIED MECHANISM-BASED PK/PD MODEL FOR ANTIBODY DRUG CONJUGATE INDUCED HEMATOTOXICITY.
    Ait-Oudhia, S.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2017, 101 (S1) : S54 - S54
  • [42] A mechanism-based PK/PD model for the preclinical prediction of QT interval prolongation by dofetilide in man
    Jonker, DM
    Leishman, D
    Willis, R
    Milligan, PA
    Jonsson, EN
    EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2004, 23 : S69 - S69
  • [43] A Mechanism-Based PK/PD Model for Hematological Toxicities Induced by Antibody-Drug Conjugates
    Sihem Ait-Oudhia
    Weiyan Zhang
    Donald E. Mager
    The AAPS Journal, 2017, 19 : 1436 - 1448
  • [44] A mechanism-based pharmacokinetic/pharmacodynamic model for CYP3A1/2 induction by dexamethasone in rats
    Li, Liang
    Li, Zai-quan
    Deng, Chen-hui
    Ning, Miao-ran
    Li, Han-qing
    Bi, Shan-shan
    Zhou, Tian-yan
    Lu, Wei
    ACTA PHARMACOLOGICA SINICA, 2012, 33 (01) : 127 - 136
  • [45] A mechanism-based pharmacokinetic/pharmacodynamic model for CYP3A1/2 induction by dexamethasone in rats
    Liang Li
    Zai-quan Li
    Chen-hui Deng
    Miao-ran Ning
    Han-qing Li
    Shan-shan Bi
    Tian-yan Zhou
    Wei Lu
    Acta Pharmacologica Sinica, 2012, 33 : 127 - 136
  • [46] Study Reanalysis Using a Mechanism-Based Pharmacokinetic/Pharmacodynamic Model of Pramlintide in Subjects with Type 1 Diabetes
    Fang, Jing
    Landersdorfer, Cornelia B.
    Cirincione, Brenda
    Jusko, William J.
    AAPS JOURNAL, 2013, 15 (01): : 15 - 29
  • [47] Study Reanalysis Using a Mechanism-Based Pharmacokinetic/Pharmacodynamic Model of Pramlintide in Subjects with Type 1 Diabetes
    Jing Fang
    Cornelia B. Landersdorfer
    Brenda Cirincione
    William J. Jusko
    The AAPS Journal, 2013, 15 : 15 - 29
  • [48] A model-based analysis of pharmacokinetic-pharmacodynamic (PK/PD) indices of avibactam against Pseudomonas aeruginosa
    Sy, S. K. B.
    Zhuang, L.
    Xia, H.
    Schuck, V. J.
    Nichols, W. W.
    Derendorf, H.
    CLINICAL MICROBIOLOGY AND INFECTION, 2019, 25 (07) : 904.e9 - 904.e16
  • [49] A New Mechanism-based PK/PD Model for Antimicrobial Combinations of Colistin and Doripenem against Pseudomonas aeruginosa
    Ly, Neang S.
    Tsuji, Brian T.
    Rao, Gauri G.
    Kelchlin, Pamela A.
    Holden, Patricia N.
    Forrest, Alan
    Bergen, Phillip J.
    Nation, Roger L.
    Li, Jian
    Bulitta, Jurgen B.
    JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS, 2013, 40 : S116 - S117
  • [50] Pharmacokinetic/pharmacodynamic (PK/PD) population model linking cortisol production with fluticasone concentration.
    Mishina, EV
    Miller, R
    Salcoz, C
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 1998, 63 (02) : 201 - 201
12345